KR20180093560A - A composition for skin whitening, anti-oxidating, astringent or anti-wrinkle comprising extracts of unripe plum - Google Patents
A composition for skin whitening, anti-oxidating, astringent or anti-wrinkle comprising extracts of unripe plum Download PDFInfo
- Publication number
- KR20180093560A KR20180093560A KR1020170019824A KR20170019824A KR20180093560A KR 20180093560 A KR20180093560 A KR 20180093560A KR 1020170019824 A KR1020170019824 A KR 1020170019824A KR 20170019824 A KR20170019824 A KR 20170019824A KR 20180093560 A KR20180093560 A KR 20180093560A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- plum
- extract
- composition
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 89
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000002087 whitening effect Effects 0.000 title claims abstract description 24
- 230000003064 anti-oxidating effect Effects 0.000 title claims abstract description 11
- 230000001153 anti-wrinkle effect Effects 0.000 title 1
- 239000002537 cosmetic Substances 0.000 claims abstract description 18
- 230000037303 wrinkles Effects 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 230000006872 improvement Effects 0.000 claims abstract description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- 230000000694 effects Effects 0.000 abstract description 52
- 230000007613 environmental effect Effects 0.000 abstract description 6
- 241000792859 Enema Species 0.000 abstract description 5
- 239000006227 byproduct Substances 0.000 abstract description 5
- 239000007920 enema Substances 0.000 abstract description 5
- 229940079360 enema for constipation Drugs 0.000 abstract description 5
- 238000012545 processing Methods 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 59
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 102000003425 Tyrosinase Human genes 0.000 description 18
- 108060008724 Tyrosinase Proteins 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 235000021018 plums Nutrition 0.000 description 16
- -1 thiol compounds Chemical class 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 102000016387 Pancreatic elastase Human genes 0.000 description 12
- 108010067372 Pancreatic elastase Proteins 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 229960005188 collagen Drugs 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000012488 sample solution Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- 230000009759 skin aging Effects 0.000 description 8
- 102000016942 Elastin Human genes 0.000 description 7
- 108010014258 Elastin Proteins 0.000 description 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 229920002549 elastin Polymers 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000002752 melanocyte Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229960004441 tyrosine Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000003212 astringent agent Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940030275 epigallocatechin gallate Drugs 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 230000037373 wrinkle formation Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 244000141353 Prunus domestica Species 0.000 description 2
- 235000011435 Prunus domestica Nutrition 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002849 elastaseinhibitory effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 240000008519 Prunus americana Species 0.000 description 1
- 235000010871 Prunus americana Nutrition 0.000 description 1
- 235000009836 Prunus pissardii Nutrition 0.000 description 1
- 244000277586 Prunus pissardii Species 0.000 description 1
- 240000005049 Prunus salicina Species 0.000 description 1
- 235000012904 Prunus salicina Nutrition 0.000 description 1
- 235000003681 Prunus ussuriensis Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- OHDRQQURAXLVGJ-AXMZSLBLSA-N azane;(2z)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-AXMZSLBLSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition for improving skin condition comprising enemas and plum extract. The composition comprising the extract of plum extract of the present invention as an active ingredient has excellent effects on antioxidation, skin whitening, convergence and wrinkle improvement, And skin side effects, so that it can be effectively used as a cosmetic composition, a pharmaceutical composition and a food composition. In addition, it is useful not only for environmental conservation but also for economic purposes, by utilizing agricultural processing by-products which are abolished in large quantities.
Description
The present invention relates to a composition for improving skin condition comprising enemas and plum extract, and more particularly to a cosmetic composition, a pharmaceutical composition and a foodstuff for antioxidation, skin whitening, convergence or wrinkle improvement containing an extract and plum extract as an active ingredient ≪ / RTI >
In general, human eyes, hair and skin color are determined by the concentration and distribution of melanin in the skin, and also depending on the type of melanin. However, it is also affected by various environmental and physiological factors such as ultraviolet rays and stress. Melanin is a series of enzymes that starts from the conversion of melanocytes in the basal layer of the epidermis to tyrosinase-mediated tyrosinase in the melanosomes of melanocytes, the amino acid tyrosine, which is converted to dopa chromium Oxidation and non-enzymatic oxidation processes. There are ultraviolet rays as a typical influential factor for the production and synthesis of melanin. In addition, genetic factors, environmental factors, hormones, foods, medicines and other chemicals act. These melanin absorbs a certain amount of ultraviolet rays to protect the skin and maintain the body temperature. However, when the skin is exposed to severe irritation and melanin is generated, freckles, senility spots, stains, brown or black spots, Or hyperpigmentation after inflammation due to dermatitis, and phototoxic reaction.
Recently, Oriental women prefer white and clean skin, and since they are used as an important criterion of beauty, development of a whitening agent for the treatment of skin pigmentation abnormality and to meet the desire for beauty is being actively carried out. Currently, in the development of a whitening agent for skin cosmetics, there is known a method of decolorizing by reducing the produced melanin pigment and a method of inhibiting the activity of tyrosinase, an enzyme that forms a melanin pigment. However, it has been known that whitening agents using tocopherol, vitamins and the like, which are used to reduce the melanin pigment, have little discoloring effect on the melanin pigment, and thus many studies have been conducted on inhibitors that inhibit the production of melanin pigment.
Conventionally, in order to improve skin whitening and skin hypercholesterolemia, an inhibitory activity against tyrosinase such as hydroquinone, ascorbic acid, kojic acid, glutathione and cysteine Have been used. However, hydroquinone exhibits a predetermined whitening effect, but it has a problem that skin irritation is serious, so that the blending amount is limited to a very small amount. Ascorbic acid is easy to be oxidized, and the cosmetic composition containing the same causes problems such as discoloration and swelling, Has a disadvantage in that the manufacturing process of the cosmetic is complicated due to insufficient stability in the solution. In addition, thiol compounds such as glutathione and cysteine have not only unpleasant odors but also problems with transdermal absorption, and their glycosides and derivatives are also highly polar, making them difficult to use as a blending component of cosmetics. In addition, vitamin C is easily oxidized in an aqueous solution state and can not produce a sustained effect.
On the other hand, human skin color is determined by the concentration and distribution of melanin in the skin. In addition to genetic factors, skin color is also affected by environmental or physiological conditions such as sunlight, fatigue and stress. Melanin is synthesized in melanocytes in the epidermis of the skin. In the melanosome of melanocytes, an enzyme called tyrosinase acts on tyrosine, a type of amino acid, resulting in dopa (DOPA), dopaquinone ), And then it is made through a non-enzymatic oxidation reaction. When such a synthesis of melanin occurs excessively in the skin, it darkens skin tone, and causes spots and freckles. Thus, inhibiting the activity of tyrosinase in the skin to inhibit the synthesis of melanin pigment not only makes it possible to whiten the skin tone to brighten the skin tone, but also to reduce skin irritation caused by ultraviolet rays, hormones and hereditary causes, It can improve constipation.
Skin is the primary organ of aging, and much research has been done in the field of cosmetics to delay or prevent it. Skin aging usually begins around the age of 25, and skin aging proceeds in earnest at around the age of 40 years. As a representative phenomenon of skin aging, sebum secretion is reduced, skin becomes dry, cell regeneration is delayed, and aging skin is piled up and skin becomes rough. In addition, the synthesis amount of collagen which supports the epidermis is reduced, and elastin (elastic fiber) is denatured to form wrinkles. In addition, skin color is stained, symptoms of pigmentation such as spots and black spots appear, and the epidermis is thinned, and skin protection function is weakened. Other phenomena include an increase in skin troubles due to a decrease in the skin barrier effect (barrier effect) associated with a decrease in skin thickness. Research related to skin aging is largely focused on strengthening the dermal-epidermal junction (DEJ), skin wrinkle-improving material, skin elasticity enhancement material, skin protecting material from ultraviolet rays and active oxygen which are major causes of skin aging It is classified into related materials and studied in depth.
Dermatological atrophy is a typical aging phenomenon after 70 years of age. Changes in the dermis are caused by a change in the number of fibroblasts and a change in the molecular weight of the extracellular matrix due to a decrease in their ability to synthesize. Specific changes include separation of collagen bundles, reduction of point polysaccharide synthesis, reduction of collagen and elastin number and diameter, degradation of collagen and elastic fibers, and expansion of blood vessels. Generally, among the various complex factors such as moisture content of the skin, collagen content, and immunity to the external environment, collagen degradation enzymes such as collagenase, collagenase and collagen, which reduce collagen production and collagen content, It is the active amount and activity of the genesis. Collagenase belongs to the group of matrix metalloproteinases (MMPs), which play an important role in substrate proteolysis. Such collagenase is known to decompose collagen 1, 2, 3, 5 by promoting its expression by ultraviolet rays, growth factors, inflammatory cytokines, and phorbol esters. Particularly, It is known that it plays a major role in photoaging due to the presence of light. In addition, metalloproteinases (MMPs) are composed of matrix proteins such as 4-type collagen fibers (MMP-2, -3), elastic fibers (MMP-2), or fibronectin or laminin (MMP-3) Lt; RTI ID = 0.0 > 1, < / RTI > and significantly increased expression in aged skin. Therefore, development of a material capable of reducing the activity of metalloproteinases has been actively carried out.
One of the functions that prevents skin aging and maintains healthy skin is convergence. The principle of convergence is the phenomenon that the skin contracts due to the formation of crosslinks by binding with the polymer flavonoids of the skin protein. The astringent agent has an action to shrink the skin and the mucosal blood vessels and has an effect of inhibiting the secretion of mucus by interrupting the cell gap and the lymphatic gap. In addition, since astringent agent has a property of binding to protein, it can generally judge degree of convergence effect according to degree of binding of hemoglobin protein with extract. Therefore, the convergence effect is to give the skin a sense of resilience and flexibility by contracting excessively opened pores and pores.
In addition, elastin fibers form crosslinks with collagen, and are skin constituents that are important for wrinkle formation that is involved in skin elasticity. The deficiency and aggregation of elastin fibers and the dramatic increase in activity of the elastase, elastase, have been found to be one of the causes of skin wrinkles. Elastase is the only enzyme capable of degrading elastin, and inhibition of it is known to be able to radically reduce wrinkles.
As the cells of the skin are exposed to oxidative stress by reactive oxygen species generated in a continuous biochemical reaction for the necessary energy supply in the human body in order to supply necessary energy in vivo, the cellular components such as lipid, protein, It changes carbohydrate and DNA oxidative damage and enzymatic activity, causing various diseases such as skin cancer, and promotes aging.
Therefore, in the field of cosmetics, research and development on functional cosmetics having antioxidation, skin whitening, convergence and wrinkle-improving effects have been actively carried out, and studies using natural substances have been continued in order to avoid toxicity or irritation to skin .
Most of the byproducts of agricultural products in natural resources are currently classified as industrial wastes and are not used. In the case of plums, the plums that are the enemy are abandoned.
Plums are in the rhubarb cherry plums and are divided into Oriental plum (Prunus salicina), Prunus domestica (Prunus domestica) and Prunus americana (North America) depending on their origin. Plums are rich in phenolic phytochemicals such as flavonoids and phenolic acids, and contain a large amount of neochlorogenic acid and rutin. In the case of red plum cultivars, anthocyanin is a small amount (Donovan et al., 1998). The antioxidant capacity of plums is lower than that of grapes, but 4 times higher than that of apples (Wang et al., 1996), and it has been reported that the pericarp contains more antioxidants than pulp (Park et al., 2012). Compared with mature plums, enemas (immature) plums contain a large amount of physiologically active substances such as flavonoids and polyphenols. Therefore, to effectively utilize agricultural processing by-products, which are disposed of in large quantities, and to activate the local economy, skin whitening, antioxidation, and wrinkle are improved by using immature plum (enameled plum) containing
Accordingly, the inventors of the present invention have continued to develop natural materials having antioxidant, whitening, astringent and wrinkle-reducing effects and fewer human side effects. As a result, it has been found that the extracts of plum and plum have antioxidant, whitening, The present invention has been completed based on the discovery that it exhibits an excellent effect in improving wrinkles.
Accordingly, a technical problem to be solved by the present invention is to provide a substance having excellent antioxidant, whitening, whitening, convergence and wrinkle-reducing effects, and excellent human stability without cytotoxicity derived from natural materials.
In order to solve the above technical problems, the present invention provides a composition for antioxidation, skin whitening, convergence and wrinkle improvement comprising an extract of plum and plum as an active ingredient.
Preferably, the composition comprising the extract and the plum extract in the present invention may be a cosmetic composition, a pharmaceutical composition or a food composition.
The term " enemas and plums "of the present invention means plums adulterated one to three weeks after flowering.
The term "extract " of the present invention means a preparation which is obtained by squeezing a herbal medicine with an appropriate leaching solution and concentrating by evaporating the leaching solution, and is not limited thereto. The extract, the diluted solution, A dried product obtained by drying, a controlled preparation thereof, or a purified product thereof.
The extract and plum extract of the present invention can be extracted using a conventional extraction solvent known in the art, and the extracted liquid can be used in a liquid form or can be used by concentration and / or drying. The extraction solvent may be, for example, (a) water, (b) anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) Solvent, (d) acetone, (e) ethyl acetate, (f) chloroform or (g) 1,3-butylene glycol as the extraction solvent. Preferably, extraction is carried out using methanol, ethanol or butane. Depending on the extraction solvent, the degree of extraction and the degree of loss of the active ingredient of the extract may differ. Therefore, an appropriate extraction solvent should be selected and used. The extraction method is not particularly limited, and examples thereof include cold extraction, ultrasonic extraction, and reflux cooling extraction.
In addition, the red and plum extracts can be obtained through a conventional purification process in addition to the extraction method using the above-mentioned extraction solvent. For example, a fraction obtained through various purification methods such as separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The extract and plum extract can be obtained.
According to one specific embodiment of the present invention, the red and plum extracts are prepared by pulverizing red and plum, and then extracting a solvent selected from the group consisting of water, an anhydrous or a lower alcohol having 1 to 3 carbon atoms, and a mixed solvent thereof, And the amount of the extraction solvent may be 2 to 4 parts by volume relative to the volume of the plum and plums.
According to one specific embodiment of the present invention, the red and plum extracts are prepared by pulverizing red and plum, adding 60 to 80% ethanol (EtOH) in a volume ratio of 1 to 4 times, To 26 hours, collected by filtration, and then concentrated by filtration to obtain a red and a plum extract.
The composition of the present invention may contain from 0.005 to 50% by weight, more preferably from 0.01 to 30% by weight, and most preferably from 0.1 to 10% by weight, of the extract and plum extract, based on the total weight of the composition. If the content of the extract is less than 0.005% by weight, antioxidation, skin whitening, convergence and wrinkle reducing effects of the present invention can not be obtained. If the content exceeds 50% by weight, There is a problem in that the stability of the shape can not be secured.
The composition containing the extract and the plum extract of the present invention exhibits antioxidant, whitening, astringent and wrinkle-reducing effects, and has little cytotoxicity as a natural substance.
According to one embodiment of the present invention, there is provided a cosmetic composition comprising an enemas and a plum extract as an active ingredient.
The cosmetic composition according to one embodiment of the present invention may contain, in addition to a red and plum extract as an active ingredient, conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, The carrier may be further added.
The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.
When the formulation of the present invention is a paste, cream or gel, use is made of an animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide .
When the formulation of the present invention is a powder or a spray, tosse, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Castellulose, aluminum metahydroxide, bentonite, agar or tracert, etc. may be used.
When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
A pharmaceutical composition according to one embodiment of the present invention comprises a pharmaceutically acceptable carrier other than the extract and the plum extract. The pharmaceutically acceptable carrier to be contained in the pharmaceutical composition of the present invention is one usually used at the time of formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
The pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably applied by parenteral administration, more preferably topical application by application.
A suitable dosage of the pharmaceutical composition of the present invention may vary depending on such factors as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate, . The dosage of the pharmaceutical composition of the present invention is in the range of 0.001-100 mg / kg on an adult basis. When the composition is an external preparation, it is preferably applied in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day, and continued for 1 month or more. However, the dose is not intended to limit the scope of the present invention.
The pharmaceutical composition of the present invention may be prepared in unit dosage form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art, Into the container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in an oil or aqueous medium, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
In addition, the food composition according to one embodiment of the present invention may contain, as an active ingredient, adipate and plum extract as well as ingredients normally added in the manufacture of food such as protein, carbohydrate, fat, nutrients, May be further included.
Examples of such carbohydrates are monosaccharides, such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.
For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, .
On the other hand, the extract and plum extract of the present invention are naturally harmless to the human body, have little toxicity and side effects, and can be safely used for long-term use. In particular, they can be safely applied to cosmetic, pharmaceutical and food compositions as described above .
As described above, the composition comprising the extract and the plum extract of the present invention as an effective ingredient has excellent effects on antioxidation, skin whitening, convergence and wrinkle improvement, and is free from cytotoxicity and skin side effects, and is useful as a cosmetic composition, a pharmaceutical composition and a food composition Lt; / RTI > In addition, it is useful not only for environmental conservation but also for economic purposes, by utilizing agricultural processing by-products which are abolished in large quantities.
FIG. 1 is a graph showing the DPPH electron donating ability according to the concentration of the extract and plum extract. FIG.
2 is a graph showing the ABTS radical scavenging activity according to the concentration of the extract and plum extract.
Fig. 3 is a graph showing the inhibitory effect of tyrosinase activity on the concentration of the extract and plum extract. Fig.
4 is a graph showing the astringent effect according to the concentration of the plum and plum extract.
5 is a graph showing an effect of inhibiting elastase according to the concentration of the extract and plum extract.
Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.
Example 1 Preparation of Red and Plum Extracts
After crushing the red and plum, 1000 ml of 70% ethanol was immersed in 100 g of the sample for 24 hours, and the solution was collected three times and collected. 2 filter paper, and the filtrate was concentrated using a vacuum rotary evaporator, lyophilized, and stored at -20 ° C.
<Test Example 1> Measurement of antioxidant effect
(1) Measurement of DPPH radical scavenging ability
The electron donating ability (EDA) was measured according to Blois's method (1958). 1 mL of 1, 1-diphenyl-2-picrylhydrazyl (DPPH) was added to 2 mL of each sample solution, and the mixture was left to stand for 30 minutes and absorbance was measured at 517 nm. The electron donating ability was expressed by the absorbance decreasing rate of the sample solution added group and the no added group.
The measurement of DPPH radical scavenging ability is a method of measuring electron donating ability as a strong antioxidant as the reducing power becomes larger. Therefore, the reducing power and the antioxidant power of the test substance can be measured based on the reduction degree of DPPH. DPPH electron donating ability, which inhibits oxidation by donating electrons of free radicals in association with the lipid peroxidation chain reaction, was measured by controlling and adding platelets and plum extract to a concentration of 10 ~ 1,000 ug / ml.
The results of DPPH scavenging activity of the extract and plum extract were shown in Table 1 and FIG. Plums and vitamin C were used for comparison.
FIG. 1 is a graph showing the DPPH electron donating ability according to the concentration of the extract and plum extract. FIG.
As shown in Table 1 and FIG. 1, the extract of plum and plum showed higher DPPH radical scavenging ability than that of general plum, and it was confirmed that the extract had better effect than vitamin C even at low concentration.
(2) Measurement of ABTS radical scavenging activity
The ABTS radical cation scavenging activity is due to the reaction of 2,2'-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) with potassium persulfate. It is a method to measure both hydrogen donating antioxidant and chain breaking antioxidant by measuring decolorization by light green as added.
Antioxidant activity using ABTS radical was measured by ABTS + cation decolorization assay (Roberta, et al., 1999). After incubation at room temperature for 24 hours, ABTS + was formed and diluted with ethanol, and the sample was added to ABTS + 0.1 mL. 0.1 mL was added, and the mixture was allowed to stand for 1 minute, and the absorbance was measured at 732 nm.
The results of ABTS radical scavenging by concentration of the extract and plum extract are shown in Table 2 and FIG. Plums and vitamin C were used for comparison.
2 is a graph showing the ABTS radical scavenging activity according to the concentration of the extract and plum extract.
As shown in Table 2 and FIG. 2, the extract and plum extract showed higher ABTS radical scavenging ability than the general plum, and it was confirmed that the extract had an excellent effect comparable to vitamin C.
<Test Example 2> Measurement of whitening effect
The inhibition activity of tyrosinase for the measurement of whitening effect was measured by the dopachrome method. To the reaction mixture, 10 μl of mushroom tyrosinase (2,000 U / ml) was added to a mixture of 10 μl of the substrate solution and 11 μl of the sample solution containing 110 μl of 0.1 M phosphate buffer (pH 6.5) dissolved in 11.5 mM L-tyrosine and incubated at 37 ° C for 15 minutes And measured at 490 nm. The DOPA oxidation inhibitory activity was measured by the absorbance reduction ratio of the sample solution with and without the sample solution.
Dihydroxy-L-phenylalanine (EC 1.14.18.1), an enzyme containing copper, is an enzyme that inhibits L-tyrosine, DOPA, and DOPA in the early stages of melanin synthesis. L-dopaquinone. Melanocyte mitosis is induced by ultraviolet light and then melanocyte is activated. In activated melanocytes, tyrosinase synthesis is promoted and melanin is produced and transported out of the epidermis, causing pigmentation such as spots and freckles. Therefore, tyrosine activity inhibitors can effectively inhibit the synthesis of melanin polymer in the skin. Thus, the inhibition of tyrosinase activity in the development of skin whitening agents has been recognized as a useful evaluation method. Thus, tyrosinase plays an important role in the melanin biosynthesis process, so tyrosinase inhibitors can be used as a substance capable of controlling melanin pigment production in the skin. 4-hydroxyanisole and hydroquinone, which are tyrosinase inhibitors, have been reported to be effective in the hyper-pigmentation treatment of human body and to inhibit the proliferation of melanoma cells.
The results of inhibition of tyrosinase activity by the concentration of the extract and plum extract are shown in Table 3 and FIG. Plums and vitamin C were used for comparison.
Fig. 3 is a graph showing the inhibitory effect of tyrosinase activity on the concentration of the extract and plum extract. Fig.
As shown in Table 3 and FIG. 3, it was confirmed that the extract and plum extract showed a higher tyrosinase activity inhibitory effect than that of the common plum.
Test Example 3 Measurement of astringent effect
One of the functions that prevents skin aging and maintains healthy skin is convergence. The principle of convergence is the phenomenon that the skin contracts due to the formation of crosslinks by binding with the polymer flavonoids of the skin protein. The astringent agent has an action to shrink the skin and the mucosal blood vessels and has an effect of inhibiting the secretion of mucus by interrupting the cell gap and the lymphatic gap. In addition, since astringent agent has a property of binding to protein, it can generally judge degree of convergence effect according to degree of binding of hemoglobin protein with extract. Therefore, the convergence effect is to give the skin a sense of resilience and flexibility by contracting excessively opened pores and pores.
To measure the convergence effect, hemoglobin, a blood protein similar to the skin protein, was used. Each sample solution and hemoglobin solution (500ppm) were mixed in a ratio of 1: 1, shaken, and centrifuged at 1,500 rpm for 3 minutes, and the absorbance was measured at 576 nm. The measurement of the convergence effect is shown by the absorbance decreasing rate of the sample solution addition group and the no addition group as shown in the following equation (1).
Convergence effects of the red and plum extracts by concentration are shown in Table 4 and FIG. Common plums and epigallocatechin gallate (EGCG) were used for comparison.
4 is a graph showing the astringent effect according to the concentration of the plum and plum extract.
As shown in Table 4 and FIG. 4, the red and plum extracts showed better astringent effect than common plums, and at high concentrations, the effect was similar to that of epigallocatechin gallate (EGCG).
Test Example 4 Measurement of wrinkle improvement effect
Elastase inhibitory activity was measured as follows. 0.5 mL of porcine pancreas elastase (2.5 U / mL) dissolved in 50 mM tris-HCl buffer (pH 8.6) was added to the test tube, and 50 mM tris-HCl buffer N-succinyl- (L-Ala) 3-p-nitroanilide (0.5 mg / mL) was added to the reaction solution for 20 minutes to measure the amount of p-nitroanilide produced from the substrate at 405 nm. Elastase inhibitory activity was expressed by the absorbance reduction ratio of the sample solution with and without the sample solution.
The matrix-metalloproteinases (MMPs) present in the dermal layer of skin induced by ultraviolet and reactive oxygen species are closely related to skin aging, especially wrinkle formation. The major constituents of MMPs are collagenase, gelatinase and elastase, which are reduced in elasticity and elasticity due to external stresses such as ultraviolet rays, and the elastin network structure by over-expressed elastase As it breaks, the skin becomes sagging and wrinkles, so it is very important to reduce the elasticity of the skin and reduce the activity of elastase in wrinkle formation. Elastase, which hydrolyzes elastin, is an enzyme associated with skin wrinkles, and the effects of red and plum extract on elastase activity were observed.
Convergence effects of the extracts of plum and plum extracts are shown in Table 5 and FIG. 5 below. For comparison, plum and ursolic acid were used.
5 is a graph showing an effect of inhibiting elastase according to the concentration of the extract and plum extract.
As shown in Table 5 and FIG. 5, the red and plum extracts showed better inhibitory effects on elastase than common plums, and showed similar effects to those of uric acid.
As described above, the composition comprising the extract and the plum extract of the present invention as an effective ingredient has excellent effects on antioxidation, skin whitening, convergence and wrinkle improvement, and is free from cytotoxicity and skin side effects, and is useful as a cosmetic composition, a pharmaceutical composition and a food composition Lt; / RTI > In addition, it is useful not only for environmental conservation but also for economic purposes, by utilizing agricultural processing by-products which are abolished in large quantities.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170019824A KR20180093560A (en) | 2017-02-14 | 2017-02-14 | A composition for skin whitening, anti-oxidating, astringent or anti-wrinkle comprising extracts of unripe plum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170019824A KR20180093560A (en) | 2017-02-14 | 2017-02-14 | A composition for skin whitening, anti-oxidating, astringent or anti-wrinkle comprising extracts of unripe plum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180093560A true KR20180093560A (en) | 2018-08-22 |
Family
ID=63452838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170019824A KR20180093560A (en) | 2017-02-14 | 2017-02-14 | A composition for skin whitening, anti-oxidating, astringent or anti-wrinkle comprising extracts of unripe plum |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20180093560A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102199082B1 (en) * | 2019-07-11 | 2021-01-06 | 인하대학교 산학협력단 | Pharmaceutical composition for preventing or treating vitiligo or canities comprising extract of Prunus armeniaca as an active ingredient |
| KR102291441B1 (en) * | 2020-02-19 | 2021-08-20 | 계명대학교 산학협력단 | Composition for skin whitening comprising plum seed extract |
-
2017
- 2017-02-14 KR KR1020170019824A patent/KR20180093560A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102199082B1 (en) * | 2019-07-11 | 2021-01-06 | 인하대학교 산학협력단 | Pharmaceutical composition for preventing or treating vitiligo or canities comprising extract of Prunus armeniaca as an active ingredient |
| KR102291441B1 (en) * | 2020-02-19 | 2021-08-20 | 계명대학교 산학협력단 | Composition for skin whitening comprising plum seed extract |
| WO2021167269A1 (en) * | 2020-02-19 | 2021-08-26 | 계명대학교 산학협력단 | Whitening composition comprising plum seed extract as active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
| KR101937344B1 (en) | A composition for skin whitening, anti-oxidating and anti-wrinkle comprising unripe apple extracts and baicalin | |
| KR101176528B1 (en) | Cosmetic composition comprising the extract of salvia plebeia as active ingredient | |
| KR20180093560A (en) | A composition for skin whitening, anti-oxidating, astringent or anti-wrinkle comprising extracts of unripe plum | |
| KR101453258B1 (en) | Health Functional Food Composition Comprising Red Ginseng Extract, Benincasa Hispida Extract, and Apios Americana Extract for Improving Skin Beauty | |
| KR101700105B1 (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of false indigo | |
| KR101980142B1 (en) | Method for producing chestnut inner shell extract with increased skin-whitening and anti-wrinkle using enzyme and autoclave treatment | |
| KR20140089305A (en) | Composition for improving skin whitening or skin wrinkle comprising extracts of Quercus salicina Blume | |
| KR20180128774A (en) | A composition for antioxidating, whitening and improving wrinkle comprising flower extract | |
| KR101904216B1 (en) | A composition for skin whitening and improving skin wrinkle comprising extracts of jujube seed | |
| KR20210134589A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
| KR20230033388A (en) | Compositions for Improving Skin Wrinkles and Skin Whitening Using an Extract of Veratrum versicolor | |
| KR20180128773A (en) | A composition for antioxidating, whitening and improving wrinkle comprising forsythia fruit oil or peony oil | |
| KR20180088173A (en) | A cosmetic composition comprising extracts of cladosiphon novae - caledoniae kylin | |
| KR20200046674A (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of black persimmon | |
| KR101936175B1 (en) | A COMPOSITION FOR ANTI-AGING COMPRISING FERMENTATION PRODUCTS OF A. koreanum | |
| KR101703527B1 (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of bombycis faeces | |
| KR101695781B1 (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of nursery spiraea | |
| KR102000688B1 (en) | A composition for anti-wrinkle comprising unripe apple extracts and baicalin | |
| KR102000687B1 (en) | A composition for anti-oxidating comprising unripe apple extracts and baicalin | |
| KR102557359B1 (en) | Cosmetic composition comprising citron residue extract and manufacturing method thereof | |
| KR102459512B1 (en) | Method for preparing complex extracts of neungi, chrysanthemum, and magnolia using Cyclodextrin Glucanotransferas and cosmetic composition containing the same | |
| KR101980144B1 (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of pleurotus salmoneostramineus | |
| KR102533787B1 (en) | Antioxidant effect on flavonoids and polyphenols of Ceratopteris thalictroides extract, and cosmetic composition for preventing skin aging, or for preventing or improving skin wrinkles | |
| KR102366932B1 (en) | Composition with Antioxidant, Anti-Inflammation, Skin Moisturizing, Anti-Wrinkle, and Skin Regeneration Property Comprising Complex Extract of Hibiscus Syriacus Softened Petal as Active Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |